Walter K Vogel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5106991/publications.pdf

Version: 2024-02-01

	840776		888059
18	531	11	17
papers	citations	h-index	g-index
18	18	18	951
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Regulation of transcription factor activity by interconnected post-translational modifications. Trends in Pharmacological Sciences, 2014, 35, 76-85.	8.7	176
2	Bcl11b represses a mature Tâ€cell gene expression program in immature CD4 ⁺ CD8 ⁺ thymocytes. European Journal of Immunology, 2010, 40, 2143-2154.	2.9	82
3	Coordinated Regulation of Transcription Factor Bcl11b Activity in Thymocytes by the Mitogen-activated Protein Kinase (MAPK) Pathways and Protein Sumoylation. Journal of Biological Chemistry, 2012, 287, 26971-26988.	3.4	50
4	Porcine m2 Muscarinic Acetylcholine Receptor-Effector Coupling in Chinese Hamster Ovary Cells. Journal of Biological Chemistry, 1995, 270, 15485-15493.	3.4	39
5	Coibamide A Targets Sec61 to Prevent Biogenesis of Secretory and Membrane Proteins. ACS Chemical Biology, 2020, 15, 2125-2136.	3.4	39
6	Site-Directed Mutagenesis on the m2 Muscarinic Acetylcholine Receptor: The Significance of Tyr403 in the Binding of Agonists and Functional Coupling. Molecular Pharmacology, 1997, 52, 1087-1094.	2.3	29
7	A de novo substitution in BCL11B leads to loss of interaction with transcriptional complexes and craniosynostosis. Human Molecular Genetics, 2019, 28, 2501-2513.	2.9	23
8	Nonmuscle myosins II-B and Va are components of detergent-resistant membrane skeletons derived from mouse forebrain. Brain Research, 2007, 1143, 46-59.	2.2	16
9	Kinetic Analysis of BCL11B Multisite Phosphorylation–Dephosphorylation and Coupled Sumoylation in Primary Thymocytes by Multiple Reaction Monitoring Mass Spectroscopy. Journal of Proteome Research, 2014, 13, 5860-5868.	3.7	16
10	Double Mutant Cycle Analysis of Aspartate 69, 97, and 103 to Asparagine Mutants in the m2 Muscarinic Acetylcholine Receptor. Archives of Biochemistry and Biophysics, 1999, 361, 283-294.	3.0	14
11	Phospholipase C- \hat{l}^2 3 and - \hat{l}^2 1 Form Homodimers, but Not Heterodimers, through Catalytic and Carboxyl-Terminal Domains. Molecular Pharmacology, 2006, 70, 860-868.	2.3	13
12	Calmodulin potentiates GÎ ² Î ³ activation of phospholipase C-Î ² 3. Biochemical Pharmacology, 2007, 73, 270-278.	4.4	11
13	PI(3,4,5)P ₃ potentiates phospholipase C- \hat{l}^2 activity. Journal of Receptor and Signal Transduction Research, 2009, 29, 52-62.	2.5	6
14	A targeted combinatorial therapy for Ewing's sarcoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 37, 102446.	3.3	6
15	Genome-wide mapping of chromatin state of mouse forelimbs. Open Access Bioinformatics, 2014, 6, 1.	0.9	5
16	Discovery and Validation of a Compound to Target Ewing's Sarcoma. Pharmaceutics, 2021, 13, 1553.	4.5	5
17	Realization of the T Lineage Program Involves GATA-3 Induction of Bcl11b and Repression of Cdkn2b Expression. Journal of Immunology, 2022, 209, 77-92.	0.8	1
18	Stoichiometry of slow binding of palmitoylâ€CoA to liver glucokinase*. International Journal of Peptide and Protein Research, 1989, 34, 333-339.	0.1	0